### Highlights of This Issue

#### SPECIAL FEATURES

**Finding the Right Dose for Cancer Therapeutics—Can We Do Better?**
Eric H. Rubin and Keaven M. Anderson  
[See article p. 1289](#)

**Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer**
Amina Zoubeidi, Kim Chi, and Martin Gleave

**Targeting the RB-pathway in Cancer Therapy**
Erik S. Knudsen and Jean Y.J. Wang

**A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations**
Eleni Efstratiou and Christopher J. Logothetis

### HUMAN CANCER BIOLOGY

**High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma**

**Frequent Downregulation of miR-34 Family in Human Ovarian Cancers**

### CANCER THERAPY: PRECLINICAL

**Comprehensive MicroRNA Profiling for Head and Neck Squamous Cell Carcinomas**
Angela Y.Y. Hui, Michelle Lenarduzzi, Tiffaney Krushel, Levi Waldron, Melania Pintilie, Wei Shi, Bayardo Perez-Ordonez, Igor Jurisica, Brian O'Sullivan, John Waldron, Pat Gullane, Bernard Cummings, and Fei-Fei Li

**X-Linked Ectodermal Dysplasia Receptor Is Downregulated in Breast Cancer via Promoter Methylation**
Vasu Punj, Hittu Matta, and Preet M. Chaudhary

**Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias**

**AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer**

**Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models**
Kazushi Watanabe, Susumu Tanimura, Aya Uchiyama, Toshiaki Sakamoto, Takumi Kawabata, Kei-ichi Ozaki, and Michiaki Kohno
Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G₁ Arrest in Human Breast Cancer Cells and Tumors
Said Akli, Tuyen Bui, Hannah Wingate, Anna Biernacka, Stacy Moulder, Susan L. Tucker, Kelly K. Hunt, and Khandan Keyomarsi

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography
Nathalie Lassau, Serge Koscielny, Laurence Albiges, Linda Chami, Baya Benatsou, Mohamed Chebil, Alain Roche, and Bernard J. Escudier

Tobacco Use in Human Papillomavirus–Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence

IMAGING, DIAGNOSIS, PROGNOSIS

A 3’-Untranslated Region Polymorphism in IGF1 Predicts Survival of Non–Small Cell Lung Cancer in a Chinese Population
Mingfeng Zhang, Zhibin Hu, Jinlin Huang, Yongqian Shu, Junchong Dai, Guanglu Jin, Rong Tang, Jing Dong, Yijiang Chen, Lin Xu, Xinen Huang, and Hongbing Shen

Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients
Peter Hammarsten, Amar Karaliya, Andreas Josefsson, Stina Hägström Rudolfsson, Pernilla Wikström, Lars Egevad, Torvald Granfors, Pär Stattin, and Anders Bergh

CANCER THERAPY: CLINICAL

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge, Roy S. Herbst, Michael S. Gordon, S. Gail Eckhardt, Razelle Kurzrock, Blythe Durbin, Josephine Ing, Tanyifor M. Tohnya, Jason Sager, Avi Ashkenazi, Gordon Bray, and David Mendelson

Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis
Florence Dalenc, Sophie F. Doisneau-Sixou, Ben C. Allal, Sabrina Marsili, Valérie Laursers-Cances, Karima Chaoui, Odile Schiltz, Bernard Monsarrat, Thomas Filleron, Nicole Renée, Emilie Malissee, Elise Meunier, Gilles Favre, and Henri Roché

The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1289</td>
<td>Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse</td>
<td>Rajul K. Jain, J. Jack Lee, David Hong, Maurie Markman, Jing Gong, Aung Naing, Jennifer Wheler, and Razelle Kurzrock</td>
</tr>
<tr>
<td>1298</td>
<td>Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer</td>
<td>Charles A. Kunos, Steven Waggoner, Vivian von Gruenigen, Elisa Eldermire, John Pink, Afshin Dowlati, and Timothy J. Kinsella</td>
</tr>
<tr>
<td>1307</td>
<td>Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy</td>
<td>Dae Ho Lee, Keunchil Park, Joo Hang Kim, Jong-Seok Lee, Sang Won Shin, Jin-Hyoung Kang, Myung-Ju Ahn, Jin Seok Ahn, Cheolwon Suh, and Sang-We Kim</td>
</tr>
<tr>
<td>1324</td>
<td>Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer</td>
<td>Shuhang Wang, Tongtong An, Jie Wang, Jun Zhao, Zhijie Wang, Minglei Zhuo, Hua Bai, Lu Yang, Yan Zhang, Xin Wang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, and Meina Wu</td>
</tr>
<tr>
<td>1331</td>
<td>Smoking and Colorectal Cancer in Lynch Syndrome: Results from the Colon Cancer Family Registry and The University of Texas M.D. Anderson Cancer Center</td>
<td>Mala Pande, Patrick M. Lynch, John L. Hopper, Mark A. Jenkins, Steve Gallinger, Robert W. Haile, Loic LeMarchand, Noralane M. Lindor, Peter T. Campbell, Polly A. Newcomb, John D. Potter, John A. Baron, Marsha L. Frazier, and Christopher I. Amos</td>
</tr>
</tbody>
</table>

**LETTERS TO THE EDITOR**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1340</td>
<td>Studies of TMPRSS2-ERG Gene Fusions in Diagnostic Trans-Rectal Prostate Biopsies</td>
<td>Gerhardt Attard, Johann S. de Bono, Jeremy Clark, and Colin S. Cooper</td>
</tr>
<tr>
<td>1340</td>
<td>In Response</td>
<td>Martin G. Sanda</td>
</tr>
<tr>
<td>1341</td>
<td>In Response</td>
<td>Emer O. Hanrahan, Anderson J. Ryan, and John V. Heymach</td>
</tr>
</tbody>
</table>

**CORRECTIONS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1343</td>
<td>Correction: A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>1343</td>
<td>Correction: The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y] Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preclinical Findings and Results of a Phase I Trial</td>
</tr>
</tbody>
</table>

The Journal of Clinical and Translational Research v www.aacrjournals.org
ABOUT THE COVER

Expression of the miR-34 family was found to be frequently reduced in human epithelial ovarian cancer, particularly so in tumors with p53 mutations. The figure shows miR-34a expression (dark blue) in ovarian serous adenocarcinoma as determined by in situ hybridization with locked nucleic acid–modified probes. Immunohistochemistry in serial sections revealed significant inverse correlation between miR-34a and its target MET, an oncogene commonly overexpressed in advanced stages of cancer. For details, see the article by Corney and colleagues on page 1119 of this issue.